Associated Papers
Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection.
Bae J et al.
Antimicrobial Agents and Chemotherapy, 2024
Insights from host genomics into HIV infection and disease: Identification of host targets for drug development.
Ballana E et al.
Antiviral Research, 2013
Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation.
Kwara A et al.
Journal of Clinical Pharmacology, 2009
The impact of pharmacogenetics on HIV therapy.
Mahungu TW et al.
International Journal of Std & Aids, 2009
The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.
Abla N et al.
The Journal of Pharmacology and Experimental Therapeutics, 2008
Evolution of pharmacogenomics.
Somogy A
Proceedings of the Western Pharmacology Society, 2008
Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.
Cressey TR et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases, 2007
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.
Anderson PL et al.
Journal of Acquired Immune Deficiency Syndromes (1999), 2006
Overview of the pharmacogenetics of HIV therapy.
Rodríguez-Nóvoa S et al.
The Pharmacogenomics Journal, 0
Select a paper to view details